Sign in
Active, not recruitingPhase 4

Dupixent Study for Alternate Administration

Key facts

Who runs it
Madigan Army Medical Center
Where
Tacoma, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
30 people, planned
Started
14 Oct 2021
Ended
Dec 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dupilumab
Record updated
17 January 2025

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age=>18 y/o with recurrent CRSwNP based on reported symptoms and endoscopic assessment
  • history of atleast 1 endoscopic sinus surgery
  • Current use of intranasal corticosteroid spray or irrigation
  • Active duty servicemembers must be in the area for at least 7 months after starting the medication to complete the necessary follow ups

Who cannot take part

  • Previous use of other biologic therapy in last 6 months
  • if history of asthma, FEV1< 50%
  • history of cystic fibrosis, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, kartagener syndrome, primary ciliary dyskinesia
  • Patient is a pregnant woman, may become pregnant or breastfeeding

Other criteria

  • Eligibility: patients =>18 years old with recurrent chronic rhinosinusitis with nasal polyposis (CRSwNP) despite standard of care (i.e topical medical therapies and full endoscopic sinus surgery)

Where in United States

  • Madigan Army Medical CenterTacoma, United States

About the trial

What the trial wants to find out

Investigators will investigate an alternate Dupilumab administration schedule in patients with recurrent chronic rhinosinusitis with nasal polyposis, who have a history of full endoscopic sinus surgery and are on appropriate topical medical therapies. Specifically, investigators will investigate if the alternate schedule of drug administration is non-inferior in both subjective and objective outcomes.

The 2 groups in the trial

  • Arm A - Regular AdminstrationExisting treatment, for comparison

    Eligible patient will receive 300 mg Subcutaneous Dupilumab every 2 weeks for 28 weeks

    Treatment: Dupilumab

  • Arm B - Alternate AdministrationTreatment being tested

    Eligible patient will receive 300 mg Subcutaneous Dupilumab every 2 weeks for 8 weeks and then every 4 weeks up until 28 weeks

    Treatment: Dupilumab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Alternate Dupilumab Schedule in Recurrent Chronic Rhinosinusitis With Nasal Polyposis Patients
Record updated
17 January 2025